An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
Description
This single-arm, long-term, open-label, study is designed to evaluate the safety, tolerability, and efficacy of atumelnant (CRN04894) in participants with congenital adrenal hyperplasia (CAH). Enrollment will be limited to individuals who completed a parent study with CRN04894 or completed treatment in a Crinetics atumelnant study, and in the opinion of the Investigator had an acceptable benefit-risk assessment in the completed study and would benefit from continued dosing in this extension study.
Approximately 150 participants will be enrolled in the study.
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites